Table 1 Clinical features of 31 patients with ovarian cancer who had previous platinum resistant relapse and were retreated with platinum
Clinical Characteristics | Number of cases (%) |
|---|---|
Age (years old) | |
< 65 | 21 (67.7) |
> 65 | 10 (32.3) |
Histology | |
High grade serous carcinoma | 21 (67.7) |
Endometrioid | 1 (3.2) |
Clear cell carcinoma | 1 (3.2) |
Undifferentiated carcinoma | 3 (9.7) |
Carcinosarcoma | 1 (3.2) |
Mixed | 1 (3.2) |
Family history of ovarian or breast cancer | |
No | 19 (61.3) |
Yes | 9 (29.0) |
Number of previous treatment lines | |
2 | 10 (32.3) |
3 | 7 (22.6) |
4 | 4 (12.9) |
5 | 6 (19.4) |
6 | 3 (9.7) |
8 | 1 (3.2) |
Platinum free interval (months) | |
< 12 | 21 (67.7) |
> 12 | 10 (32.3) |
Primary platinum resistance* | |
No | 12 (38.7) |
Yes | 19 (61.3) |
Chemotherapy with platinum rechallenge | |
Platinum + taxane | 15 (48.4) |
Platinum + gemcitabina | 13 (41.9) |
Platinum + doxorubicin | 1 (3.2) |
Platinum + ifosfamide | 1 (3.2) |
Monotherapy | 1 (3.2) |